Stock listing

Kalvista Pharmaceuticals, Inc.

Selected listing: 4XC1 · DUS · EUR · DE

Kalvista Pharmaceuticals, Inc. (Dusseldorf:4XC1), Health Technology. Latest release Jun 11, 2026: Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

4XC1:DUSEURDEUpdated October 1, 2026

Ticker: Dusseldorf:4XC1
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Dusseldorf
Currency: EUR

Latest news from Kalvista Pharmaceuticals, Inc.

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

June 11, 2026

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

May 28, 2026

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

April 29, 2026

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

April 7, 2026

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

March 29, 2026

All Kalvista Pharmaceuticals, Inc. news →

Events

Replays

KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call
Tue, Nov 11, 2025 · 08:30 AM ET
Watch
KalVista Pharmaceuticals, Inc. (KALV) Q2 2025 Earnings Call
Thu, Sep 11, 2025 · 08:30 AM ET
Watch

Research Kalvista Pharmaceuticals, Inc.

Kalvista Pharmaceuticals, Inc. company profile

View the public company page for Kalvista Pharmaceuticals, Inc. on 6ix.

Kalvista Pharmaceuticals, Inc. news

Read company news and market updates connected to Kalvista Pharmaceuticals, Inc..

Kalvista Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Kalvista Pharmaceuticals, Inc..